# Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

> **NCT06906341** · PHASE2 · RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 270 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
- Endometrial Cancer

## Interventions

- **DRUG:** Relacorilant 150 mg once daily (QD)
- **DRUG:** Nab-paclitaxel 80 mg/m^2
- **DRUG:** Bevacizumab 10 mg/kg

## Key facts

- **NCT ID:** NCT06906341
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906341, "Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06906341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*